ArticleBMC microbiology2026
Antiadhesive and antibiofilm potential of Bacillus clausii derived biosurfactant against Streptococcus mutans, Enterococcus faecalis, and Candida albicans biofilms.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOral biofilms are principal drivers of oral and dental diseases such as caries, periodontal disease, endodontic infections, and candidiasis. Conventional biocides can reduce microbial load but may irritate tissues and disturb oral homeostasis, limiting prolonged use. Biosurfactants represent a sustainable alternative strategy by modulating adhesion and biofilm structure rather than relying solely on direct bactericidal activity. Lipopeptide biosurfactants are particularly attractive due to their amphiphilic structure, surface activity, and reported antibiofilm properties. F7 is a crude biosurfactant produced by Bacillus clausii isolated from a crude-oil reservoir in Sumatra, Indonesia. This study evaluated its physicochemical properties and antiadhesive/antibiofilm activity against three clinically relevant oral pathogens: Streptococcus mutans, Enterococcus faecalis, and Candida albicans, in both single- and mixed-species biofilm models.
resultsFourier transform infrared spectroscopy (FTIR) analysis revealed absorption bands consistent with a lipopeptide biosurfactant. F7 reduced surface tension to 22 mN/m (critical micelle concentration (CMC) 158 mg/L; emulsification index 63%), confirming strong surface activity. No planktonic minimum inhibitory concentration (MIC) or minimum bactericidal concentration (MBC)/minimum fungicidal concentration (MFC) was observed within 0.6-10 mg/mL. However, at 10 mg/mL, the minimum biofilm inhibitory concentration (MBIC) of F7 against single-species were 43.5% (S. mutans), 40.9% (E. faecalis), and 78.8% (C. albicans), and the minimum biofilm eradication concentration (MBEC) were 50.0%, 43.5%, and 34.8%, respectively. In mixed-species models at 10 mg/mL, MBIC was 23.4% (S. mutans-C. albicans), 44.7% (E. faecalis-C. albicans), and 27.6% (three-species), whereas MBEC was 74.0% (S. mutans-C. albicans), 42.8% (E. faecalis-C. albicans), and 42.5% (three-species). Resazurin assays demonstrated concordant metabolic suppression, and field emission scanning electron microscopy (FESEM) revealed membrane and matrix-associated structural alterations consistent with surface-active lipopeptide activity.
conclusionUnder the conditions tested, F7 functioned as an antibiofilm agent rather than a classical planktonic biocide. Notably, strong biofilm inhibition was observed against C. albicans, and the greatest biofilm reduction occurred in the mixed S. mutans-C. albicans consortium, accompanied by suppression of metabolic viability. These findings support a biofilm-modulating mechanism and suggest the potential of B. clausii-derived biosurfactants as non-biocidal adjuncts in oral biofilm management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.